#1O PROSOMNUS May 2022 Company Introduction 8 SLEEP TECHNOLOGIES#2Disclaimer O PROSOMNUS SLEEP TECHNOLOGIES This presentation is for informational purposes only and has been prepared to assist interested parties in making their own evaluation with respect to the proposed business combination between Lakeshore Acquisition I Corp. ("Lakeshore") and ProSomnus Holdings Inc. ("ProSomnus"). The information contained herein does not purport to be all-inclusive and none of Lakeshore, ProSomnus or any of their prospective affiliates, or any of their control persons, officers, directors, employees or representatives makes any representation or warranty, express or implied, as to the accuracy, completeness or reliability of the information contained in this presentation. It is not intended to form the basis of any investment decision or any other decision in respect of the business combination. You should not construe the contents of this presentation as investment, legal, business or tax advice. You should consult with your own counsel, financial advisor and tax advisor as to legal, business, financial, tax and related matters concerning the matters described herein. Important Information About the Proposed Business Comb ation and Where to Find It In connection with the proposed business combination, Lakeshore intends to file a Registration Statement on Form S-4, including a preliminary proxy statement/prospectus and a definitive proxy statement/prospectus with the SEC. Lakeshore's shareholders and other interested persons are advised to read, when available, the preliminary proxy statement/prospectus and the amendments thereto and the definitive proxy statement/prospectus as well as other documents filed with the SEC in connection with the proposed business combination, as these materials will contain important information about ProSomnus, Lakeshore, and the proposed business combination. When available, the definitive proxy statement/prospectus and other relevant materials for the proposed business combination will be mailed to shareholders of Lakeshore as of a record date to be established for voting on the proposed business combination. Shareholders will also be able to obtain copies of the preliminary proxy statement/prospectus, the definitive proxy statement/prospectus, and other documents filed with the SEC that will be incorporated by reference therein, without charge, once available, at the SEC's website at www.sec.gov, or by directing a request to: www.lakeshoreacquisition.com. Participants in the Solicitation Lakeshore and its directors and executive officers may be deemed participants in the solicitation of proxies from Lakeshore's shareholders with respect to the business combination. A list of the names of those directors and executive officers and a description of their interests in Lakeshore will be included in the proxy statement/prospectus for the proposed business combination and be available at www.sec.gov. Additional information regarding the interests of such participants will be contained in the proxy statement/prospectus for the proposed business combination when available. ProSomnus and its directors and executive officers may also be deemed to be participants in the solicitation of proxies from the shareholders of Lakeshore in connection with the proposed business combination. A list of the names of such directors and executive officers and information regarding their interests in the proposed business combination will be included in the proxy statement/prospectus for the proposed business combination. Forward-Looking Statements Except for historical information contained herein, this presentation contains certain "forward-looking statements" within the meaning of the federal U.S. securities laws with respect to the proposed business combination between Lakeshore and ProSomnus, the benefits of the transaction, the amount of cash the transaction will provide ProSomnus, the anticipated timing of the transaction, the services and markets of ProSomnus, our expectations regarding future growth, results of operations, performance, future capital and other expenditures, competitive advantages, business prospects and opportunities, future plans and intentions, results, level of activities, performance, goals or achievements or other future events. These forward-looking statements generally are identified by words such as "anticipate," "believe," "expect," "may," "could," "will," "potential," "intend," "estimate," "should," "plan," "predict," or the negative or other variations of such statements, reflect our management's current beliefs and assumptions and are based on the information currently available to our management. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual results or developments to differ materially from those expressed or implied by such forward-looking statements, including but not limited to: (i) the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect the price of Lakeshore's securities; (ii) the risk that the transaction may not be completed by Lakeshore's business combination deadline and the potential failure to obtain an extension of the business combination deadline if sought by Lakeshore; (iii) the failure to satisfy the conditions to the consummation of the transaction, including the approval of the business combination agreement by the stockholders of Lakeshore, the satisfaction of the minimum cash amount following any redemptions by Lakeshore's public stockholders and the receipt of certain governmental and regulatory approvals; (iv) the lack of a third-party valuation in determining whether or not to pursue the proposed transaction; (v) the occurrence of any event, change or other circumstance that could give rise to the termination of the business combination agreement; (vi) the effect of the announcement or pendency of the transaction on ProSomnus's business relationships, operating results and business generally; (vii) risks that the proposed transaction disrupts current plans and operations of ProSomnus; (viii) the outcome of any legal proceedings that may be instituted against ProSomnus or Lakeshore related to the business combination agreement or the proposed transaction; (ix) the ability to maintain the listing of Lakeshore's securities on a national securities exchange; (x) changes in the competitive industries in which ProSomnus operates, variations in operating performance across competitors, changes in laws and regulations affecting ProSomnus's business and changes in the combined capital structure; (xi) the ability to implement business plans, forecasts and other expectations after the completion of the proposed transaction, and identify and realize additional opportunities; (xii) the risk of downturns in the market and ProSomnus's industry including, but not limited to, as a result of the COVID-19 pandemic; (xiii) costs related to the transaction and the failure to realize anticipated benefits of the transaction or to realize estimated pro forma results and underlying assumptions, including with respect to estimated stockholder redemptions; (xiv) the inability to complete its convertible debt financing; (xv) the risk of potential future significant dilution to stockholders resulting from lender conversions under the convertible debt financing; and (xvi) risks and uncertainties related to ProSomnus's business, including, but not limited to, risks relating to the uncertainty of the projected financial information with respect to ProSomnus; risks related to ProSomnus's limited operating history, the roll-out of ProSomnus's business and the timing of expected business milestones; ProSomnus's ability to implement its business plan and scale its business, which includes the recruitment of healthcare professionals to prescribe and dentists to deliver ProSomnus oral devices; the understanding and adoption by dentists and other healthcare professionals of ProSomnus oral devices for mild-to-moderate OSA; expectations concerning the effectiveness of OSA treatment using ProSomnus oral devices and the potential for patient relapse after completion of treatment; the potential financial benefits to dentists and other healthcare professionals from treating patients with ProSomnus oral devices and using ProSomnus's monitoring tools; ProSomnus's potential profit margin from sales of ProSomnus oral devices; ProSomnus's ability to properly train dentists in the use of the ProSomnus oral devices and other services it offers in their dental practices; ProSomnus's ability to formulate, implement and modify as necessary effective sales, marketing, and strategic initiatives to drive revenue growth; ProSomnus's ability to expand internationally; the viability of ProSomnus's intellectual property and intellectual property created in the future; acceptance by the marketplace of the products and services that ProSomnus markets; government regulations and ProSomnus's ability to obtain applicable regulatory approvals and comply with government regulations, including under healthcare laws and the rules and regulations of the U.S. Food and Drug Administration; and the extent of patient reimbursement by medical insurance in the United States and internationally. The foregoing list of factors is not exclusive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of proxy statement, when available, and other documents filed by Lakeshore from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date on which they are made, and neither ProSomnus nor Lakeshore assume any obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements. Neither Lakeshore nor ProSomnus gives any assurance that either Lakeshore or ProSomnus, or the combined company, will achieve its expectations. 2 STRICTLY CONFIDENTIAL#3Disclaimer (cont.) O PROSOMNUS SLEEP TECHNOLOGIES Use of Projections and Non-GAAP Measures This presentation is for informational purposes only and has been prepared to assist interested parties in making their own evaluation with respect to the proposed business combination between Lakeshore Acquisition I Corp. ("Lakeshore") and This presentation contains projected financial information with respect to ProSomnus, namely revenue, gross margin and EBITDA for ProSomnus's fiscal years ended December 31, 2022 through December 31, 2025. Such projected financial information constitutes forward-looking information and is for illustrative purposes only and should not be relied upon as necessarily being indicative of future results. The assumptions and estimates underlying such projected financial information are inherently uncertain and are subject to a wide variety of significant business, economic, competitive and other risks and uncertainties that could cause actual results to differ materially from those contained in the prospective financial information. See "Forward- Looking Statements" above. Actual results may differ materially from the results contemplated by the projected financial information contained in this presentation, and the inclusion of such information in this presentation should not be regarded as a representation by any person that the results reflected in such projections will be achieved. Neither the independent auditors of Lakeshore nor the independent auditors of ProSomnus, audited, reviewed, compiled, or performed any procedures with respect to the projections for the purpose of their inclusion in this presentation, and accordingly, neither of them expressed an opinion or provided any other form of assurance with respect thereto for the purpose of this presentation. While ProSomnus, Lakeshore, and their respective financial advisors have reviewed such projections and believe them to be based on reasonable assumptions, projections are inherently unreliable and the review of such projections or their inclusion in this presentation or elsewhere is not a guarantee of ProSomnus's financial results. If the projections are not met, it could result in a complete loss of your investment. You should review the projections and underlying assumptions carefully and make your own independent determination of the likelihood of ProSomnus meeting such projections. The financial information and data contained in this presentation is unaudited and does not conform to Regulation S-X. Accordingly, such information and data may not be included in, may be adjusted in or may be presented differently in, any proxy statement, registration statement, or prospectus to be filed by Lakeshore with the SEC. Some of the financial information and data contained in this presentation are not measures prepared in accordance with United States generally accepted accounting principles ("GAAP"). EBITDA is a non-GAAP financial measure that ProSomnus defines as Operating Income plus depreciation and amortization. Lakeshore and ProSomnus believe this non-GAAP measure of financial results provides useful information to management and investors regarding certain financial and business trends relating to ProSomnus's financial condition and results of operations and an additional tool for investors to use in evaluating projected operating results and trends in and in comparing ProSomnus' financial measures with other similar companies, many of which present similar non-GAAP financial measures to investors. ProSomnus management does not consider this non-GAAP measure in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of this non-GAAP financial measure is that it excludes significant expenses and income that is required by GAAP to be recorded in ProSomnus's financial statements. In addition, it is subject to inherent limitations as it reflects the exercise of judgments by management about which expense and income items are excluded or included in determining this non-GAAP financial measures. In order to compensate for these limitations, management presents this measure (EBITDA) with the most closely related GAAP result (net income). In addition, all ProSomnus historical financial information included herein is preliminary and subject to change pending finalization of the fiscal year 2020 and 2021 audits of ProSomnus in accordance with PCAOB auditing standards. No Representations or Warranties This presentation does not purport to contain all of the information that may be required to evaluate a possible transaction. No representation or warranty, express or implied, is or will be given by Lakeshore or ProSomnus or any of their respective affiliates, directors, officers, employees, or advisers or any other person as to the accuracy or completeness of the information in this presentation (including as to the accuracy or reasonableness of statements, estimates, targets, projections, assumptions, or judgments) or any other written, oral, or other communications transmitted or otherwise made available to any party in the course of its evaluation of a possible transaction, and no responsibility or liability whatsoever is accepted for the accuracy or sufficiency thereof or for any errors, omissions, or misstatements, negligent or otherwise, relating thereto. Accordingly, none of Lakeshore or ProSomnus or any of their respective affiliates, directors, officers, employees, or advisers or any other person shall be liable for any direct, indirect, or consequential loss or damages suffered by any person as a result of relying on any statement in or omission from this presentation and any such liability is expressly disclaimed. This presentation is not intended to constitute and should not be construed as investment advice and does not constitute investment, tax, or legal advice. Certain information contained herein has been derived from sources prepared by third parties. While such information is believed to be reliable for the purposes used herein, none of Lakeshore, ProSomnus, their respective affiliates, nor Lakeshore's or ProSomnus's or their affiliates' directors, officers, employees, members, partners, shareholders, or agents makes any representation or warranty with respect to the accuracy of such information. No Offer or Solicitation This presentation shall not constitute a solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the proposed business combination. This presentation shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom. 3 STRICTLY CONFIDENTIAL#4Key Messages ProSomnus precision devices are well-positioned to become the leading treatment for Obstructive Sleep Apnea ("OSA"), one of the few remaining underserved Med Tech markets Large, growing, underserved disease with significant comorbidities PROSOMNUS SLEEP TECHNOLOGIES Limitations of current therapies (CPAP) result in inadequate alleviation, and do not offer the remote physiologic monitoring data that physicians need to better manage the disease ProSomnus is a pioneer of precision Oral Appliance Therapy ("OAT"), a new category of devices associated with better outcomes and patient preference Proven product effectiveness, business model, and ability to scale - Launch of novel, continuous patient monitoring platform is expected to transform clinicians' ability to better manage the disease with critical, real-time physiologic data Proprietary, digital manufacturing platform enables clinically meaningful precision therapy advantages and quality for customized devices 4 STRICTLY CONFIDENTIAL#5ProSomnus is Changing the Way OSA is Treated ProSomnus is the first manufacturer of precision, mass-customized OAT devices KEY ATTRIBUTES ProSomnus precision devices are individualized to match the patient's anatomy and treatment plan with precision (less than 0.5 millimeters variance to the prescription) Precision enables better effectiveness, fewer side effects and greater patient satisfaction i Clinically-proven to be more effective with better adherence than other treatment alternatives¹ Platform for remote monitoring of key physiological and therapeutic metrics Reimbursed by private medical insurance and Medicare Scalable, digital manufacturing platform 2019 Inc. 5000 LIST 2019 S FASTEST 2020 T-GROWING 2020 Inc. Inc. 5000 5000 LIST PRIVATE COMPANIES 20 CE FDA U.S.ARMY UNITED STATES PATENT AND TRADEMARK OFFICE uspto PROSOMNUS TO DATE 150,000+ Patients Treated to Date $14 Million 2021 Net Revenue ~70% 2021 Revenue Growth & 2021-2023E Revenue CAGR PROSOMNUS SLEEP TECHNOLOGIES ProSomnus EVO Most Prescribed OAT Device in the United States 1. Effectiveness defined as efficacy times adherence 2. Benjafield AV et al. Estimation of the global prevalence and burden of obstructive sleep apnea: a literature-based analysis. Lancet Respir Med. 2019 Aug 7. cites that as of 2019 an estimated 936 million adults aged 30-69 have mild to moderate OSA, as such we estimate >1 billion global OSA sufferers 3. Assumes 32% prevalence of OSA (Benjafield et al. 2019 Aug 7), multiplied by North American adult population of approximately 230 million as provided by OECD 4. Diagnosis rate of 20%, cited in Harvard Medical School. THE PRICE OF FATIGUE. December, 2010, with assumed increase of approximately 400 basis points by 2020. ~80% CPAP modality prescription rate cited in same Harvard study 5. Represents North American market failures of ~50% cited in Catcheside PG. Predictors of continuous positive airway pressure adherence. F1000 Med Rep. 2010 Sep 23 6. Calculated as ~70mm sufferers (Benjafield et al. 2019 Aug 7) multiplied by estimated diagnosis rate of ~24% (20% citied in Harvard. December 2010), multiplied by the CPAP modality prescription rate of 80% (Harvard: December 2010), multiplied by the CPAP therapy failure rate of 50% (Catcheside PG. 2010 Sep 23) LARGE, UNDERSERVED MARKET OPPORTUNITY 1+ Billion Global OSA Sufferers² 70+ Million North American OSA Sufferers³ 7+ Million North American CPAP Failures4,5,6 5 STRICTLY CONFIDENTIAL#6Significant Disruption of OSA Market is Set to Occur X X Low patient adherence X Social stigma surrounding therapy Discomfort, confinement Occurrence of upper airway infection, dry-throat and nasal skin irritation X X X 3 X CPAP Manual, time-intensive cleaning regiment required Costly with large out-of-pocket expenditures Respiratory flow data provides limited clinical utility Which would you choose? PROSOMNUS SLEEP TECHNOLOGIES PROSOMNUS SLEEP TECHNOLOGIES Clinically proven therapy High patient adherence None of the side effects of legacy OAT devices Ease of use with minimal cleaning and device maintenance required Minimal disruption to patient sleeping habits / routines Cost-effective Ability to provide continuous oxygen data which contains predictive medical value 6 STRICTLY CONFIDENTIAL#7Initiatives Underway to Drive Potential Significant Growth North America Sales Force Expansion Direct-to-Consumer Marketing and Clinician Education Future Product Opportunities: O Adjacent Medical Applications (COPD) PROSOMNUS SLEEP TECHNOLOGIES Adjacent Dental Indications (Aligners) Expanded OSA Indications PROSOMNUS SLEEP TECHNOLOGIES International Expansion 3 Й Launch of Novel Continuous Patient Monitoring Device Auto-Titrating Devices 7 STRICTLY CONFIDENTIAL#8OSA is Highly Prevalent and Associated with Major Health Consequences ■ OSA is the recurrent collapse of the airway during sleep resulting in oxygen shortages and subconscious arousals OSA is associated with comorbidities and excessive daytime sleepiness ■ CPAP, which forces air down the patient's throat, is the primary incumbent therapy ■ ■ ■ OSA is underdiagnosed, yet diagnosis is getting easier due to increased awareness and technology WHAT IS SLEEP APNEA Initiatives include public awareness and advanced in-home screening technology COMORBIDITIES¹ Untreated OSA is associated with a 4-5 fold increase in mortality² Stroke 63% Morbid Obesity 77% Type 2 Diabetes 72% Drug-Resistant Hypertension 83% Congestive Heart Failure 76% Angina / CAD 57% Atrial Fibrillation 49% Open Airway O Obstructed Airway NON-OBSTRUCTED AIRWAY PROSOMNUS SLEEP TECHNOLOGIES Tongue OBSTRUCTED AIRWAY Tongue 1. Provided at fryedental.com/services-sleep-apnea, accessed 2021 Dec 21; copyright 2018 DREAMSLEEP, LLC, statistic sources available at dreamsleep.rest/resources 2. Young, Terry & Finn, Laurel & Peppard, Paul & Szklo-Coxe, Mariana & Austin, Diane & Nieto, F & Stubbs, Robin & Hla, Khin. (2008). Sleep Disordered Breathing and Mortality: Eighteen-Year Follow-up of the Wisconsin Sleep Cohort. Sleep. 31. 1071-8. 10.3410/f.1120845.580647 8 STRICTLY CONFIDENTIAL#9Too Many People Globally Continue to suffer from OSA We believe that ProSomnus is poised to disrupt the large and growing OSA market benefiting from the improving diagnosis rates, while presenting a preferred alternative to existing therapies Expected increase in diagnosis rates driven by physician and general population awareness of OSA with large undiagnosed population Significant number of patients who have failed CPAP in North America alone, with failure rate of ~50%5 Increase in consumer-friendly therapies and devices such as those from Align, Dexcom and Inspire Major shift occurring towards at-home testing and remote monitoring, facilitating access to care LARGE AND GROWING OPPORTUNITY 2009 1. 2. 5% 3. OSA DIAGNOSIS RATES ARE TRENDING HIGHER 3 20% 2019 Significant untapped opportunity as rate of diagnosis continues to expand 100% Benjafield AV et al. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature- based analysis. Lancet Respir Med. 2019 Aug 7. Cites that as of 2019 an estimated 936 million adults aged 30-69 have mild to moderate OSA, as such we estimate >1 billion global OSA sufferers Assumes 32% prevalence of OSA (Benjafield et al. 2019 Aug 7), multiplied by North American adult population of approximately 230 million as provided by OECD Diagnosis rate of ~20%, cited in Harvard Medical School. THE PRICE OF FATIGUE. December, 2010, with assumed increase of approximately 400 basis points by 2020 5. 6. TOTAL ADDRESSABLE MARKET (POPULATION) Global OSA Sufferers North American OSA Sufferers North American OSA Diagnoses North American CPAP Users 4. Approximated using 18mm North American diagnoses and ~80% CPAP modality prescription rate (cited in Harvard Medical School. THE PRICE OF FATIGUE. December, 2010) Represents North American market failures of ~50% cited in Catcheside PG. Predictors of continuous positive airway pressure adherence. F1000 Med Rep. 2010 Sep 23 Calculated as 18mm diagnosed North American sufferers multiplied by the CPAP modality prescription rate of ~80% (Harvard: December 2010), multiplied by the CPAP therapy failure rate of ~50% (Catcheside PG. 2010 Sep 23) PROSOMNUS SLEEP TECHNOLOGIES Failed CPAP >1bn¹ ~74mm² ~18mm³ ~15mm4 ~7mm6 9 STRICTLY CONFIDENTIAL#10Medical Insurance Reimbursement Economics are Attractive for all Stakeholders TYPICAL CARE PATHWAY Evaluation Diagnostic Sleep Study On-Site or At Home Sleep Physician Step 1: Sleep Dentist Orders ProSomnus Device ■ Sleep dentist prescribes ProSomnus oral appliance and places order for device TYPICAL REIMBURSEMENT PROCESS AND ECONOMICS 1. ProSomnus Management Estimates Selection of Treatment Modality Surgery / Upper Airway Stimulation Step 2: ProSomnus Sells Device for ~$500-600 ■ ProSomnus receives order and manufactures device ▪ Average selling price of ~$500-600 CPAP OAT ENT ■ Respiratory Therapist Dental Sleep Provider Therapy Providers Medical Insurance & Pre-Approval Medical Insurance & Pre-Approval Medical Insurance & Pre-Approval O PROSOMNUS SLEEP TECHNOLOGIES Surgery & Calibration CPAP Fitting & Titrating OAT Fitting & Titration Step 3: Sleep Dentist Is Reimbursed by Medical Insurance Provider Commercial Insurance in the US Well-established commercial reimbursement for OAT, with ranges from $2,000 to $3,500¹ ■ Medicare in the US There is no published fee schedule but allowables tend to range from $1,250 to $1,800 based on geography¹ I Reimbursement Outside of the US Reimbursement varies by country Fully reimbursed in many major countries: Germany, France, Netherlands, Belgium, UK and Sweden Partially reimbursed or completely out of pocket in others 10 STRICTLY CONFIDENTIAL#11Effectiveness of Incumbent Therapies is Limited ProSomnus has superior effectiveness over incumbent therapies "I've been looking for a solution for sleep apnea for over a decade now. I'm looking forward to not being tired during the day and having more energy. Because of ProSomnus, I feel like I have a new lease on life." -Phil (Orange County, CA) 1. 2. 3. EFFECTIVENESS = ADHERENCE * EFFICACY ProSomnus adherence: Stern, J. Efficacy and Effectiveness 2018 Jun; ProSomnus efficacy: Mosca et al. JCSM 2022; 18(3):911-919. CPAP adherence and efficacy: Dieltjens M, et al. Oral Appliances in Obstructive Sleep Apnea 2019 Nov 8 Upper Airway Stimulation Adherence: Thaler et al. Results of the ADHERE UAS Registry. PROSOMNUS SLEEP TECHNOLOGIES (Mild/Moderate) PROSOMNUS SLEEP TECHNOLOGIES (All Severities) 4. CPAP Upper Airway Stimulation Legacy OAT 1 1 2 3 4 50% 48% 45% O 74% Laryngoscope (130) 2020. UAS Efficacy: Strollo, STAR Trial Group. Upper-airway stimulation for obstructive sleep apnea. N Engl J Med. 2014 Jan 9 Legacy OAT adherence: Dieltjens M, et al. Objectively Measured vs. Self-Reported Compliance 2013 Nov; Legacy OAT efficacy: Dieltjens M et al. Oral Appliances in OSA 2019 Nov PROSOMNUS SLEEP TECHNOLOGIES 85% 11 STRICTLY CONFIDENTIAL#12We Believe That ProSomnus is the Only Therapy That Meets AASM Gold Standard for Adherence ProSomnus devices are biomechanically designed to address CPAP's limitations on adherence, leading to a 61% better mean nightly use in clinical studies4 ADHERENCE - HOURS WORN PROSOMNUS SLEEP TECHNOLOGIES CPAP Upper Airway Stimulation 5. 6. Legacy OAT 1 2 3 4 4.5 Hours AASM "Gold Standard" 7 hours5 N/A There is no objective data utilizing FDA cleared sensors to support adherence rates for Legacy OAT Experimental data suggests 6.4 hours 61% 5.7 Hours 7.2 Hours 1. Stern, J. Efficacy and Effectiveness. Annual Meeting of the AADSM, 2018 Jun 2. Dieltjens M, Vanderveken O. Oral Appliances in Obstructive Sleep Apnea. Healthcare (Basel). 2019 Nov 8. Cites 56% compliance for CPAP users. Estimated hours worn based on assumed 8-hour night. 3. Thaler et al. Results of the ADHERE UAS Registry. Laryngoscope (130) 2020 4. Dieltjens M, et al. Objectively Measured vs. Self-Reported Compliance 2013 Nov Gold Standard defined as usage of the device for a minimum of 7 hours per night, based on AASM's recommendation of 7 or more hours of sleep per night for adults ProSomnus EVO IRB survey. AASM Scientific Abstract Presentation 2021. PROSOMNUS SLEEP TECHNOLOGIES 100% Patient Satisfaction/Preference Leads to Strong Adherence 12 STRICTLY CONFIDENTIAL#13ProSomnus Efficacy Comparable to CPAP for Mild and Moderate OSA PROSOMNUS SLEEP TECHNOLOGIES Precision customized oral devices continue to outperform legacy oral devices while achieving rates consistent with CPAP EFFICACY FOR MILD/MODERATE OSA PROSOMNUS SLEEP TECHNOLOGIES CPAP Upper Airway Stimulation Legacy OAT 1 2 2 N/A (Severe Only) 56% 94% 90% Efficacy does not factor in adherence challenges associated with CPAP 1. Mosca et al. JCSM 2022; 18(3):911-919. 2. Dieltjens M, Vanderveken O. Oral Appliances in Obstructive Sleep Apnea. Healthcare (Basel). 2019 Nov 8 3. Benjafield AV, et al. 2019 Aug 7, assumed even split between moderate and severe as provided by management DISEASE STATE BY SEVERITY³ ProSomnus Precision OAT a Leading Option for ~80% of Sufferers Severe, 21% Moderate, 21% Mild, 58% PROSOMNUS'S SEVERE INDICATION OPPORTUNITY ▪ ProSomnus has received FDA approval for a study protocol to investigate a severe OSA indication Patient enrollment expected Q2 '22 ▪ Retrospective cohort analysis demonstrates that ProSomnus can safely and effectively treat severe OSA ■ Medical insurance guidelines already support treatment of severe OSA with ProSomnus 13 STRICTLY CONFIDENTIAL#14In Summary, ProSomnus Delivers Outstanding Clinical Results and a Patient Preferred Experience ProSomnus delivers superior outcomes while limiting side effects and reducing costs Prescription Drivers Effectiveness Clinical Efficacy (Mild or Moderate OSA) Adherence Absence of Side Effects Economical Patient Preference Remote Patient Monitoring Source: Management Estimates Definition Nightly disease symptom resolution Disease symptom alleviation in lab, single night Nightly adherence with treatment plan Introduction of secondary, undesirable effects Up-front and ongoing cost to patient A patient's likelihood to select therapy over others Reliable and valuable data for physicians CPAP Legacy OAT: Arbitrary Jaw Thrust Legacy OAT: Jaw Expansion PROSOMNUS SLEEP TECHNOLOGIES PROSOMNUS SLEEP TECHNOLOGIES ProSomnus Precision OAT 14 STRICTLY CONFIDENTIAL#15The ProSomnus Difference: Precision, Personalized Sleep Medicine Therapy ProSomnus manufactures one of the only devices to meet AADSM standards THE ONLY PRECISION SLEEP MEDICINE DEVICE Patented Technologies Titration Mechanism: Iterative Titration Mechanism: 90 Degree Precision Prescription Transfer Engineered Materials Biomechanics: Personalization Biomechanics: True Anatomy Guidelines Establish ≤ 1 millimeter as Definition for Precision PRECISION PRESCRIPTION TRANSFER O Prescription Transfer Error (in millimeters)¹ Legacy OAT PROSOMNUS SLEEP TECHNOLOGIES 0.3 Efficacy Loss % as a Function of Prescription Transfer Error² Legacy OAT PROSOMNUS SLEEP TECHNOLOGIES 3% PROSOMNUS SLEEP TECHNOLOGIES OTHER ADVANTAGES OF PROSOMNUS Iterative titration, no metal ✓ ~30% smaller overall profile³ ~4.5x larger area for tongue space³ ~8.5x more hygienic based on 10-day color-difference test4 No clinically or statistically significant tooth movement5 Only Medical Grade Class VI certified material ✓Lower profile 1. Hu, J. et al. Abstract presented at 2020 AADSM meeting 2. Implication of Kato, 2000, applied to prescription transfer error and difference in lingual space 3. Hu, J. et al. Abstract presented at 2021 AADSM meeting and Company data; in comparison to legacy OAT 4. Gelb, M. Say No to Bio-Gunk. Dental Sleep Insider. 2018; in comparison to legacy OAT 5. Vranjes N, Santucci G, Schulze K, Kuhns D, Khai A. Assessment of potential tooth movement and bite changes with a hard- acrylic sleep appliance: A 2-year clinical study. J Dent Sleep Med. 2019 3.7 37% 15 STRICTLY CONFIDENTIAL#16Proprietary, Digital Manufacturing Capabilities Enable ProSomnus's Precision Performance Advantages Tailored in-house manufacturing processes and patented, proprietary technologies enable better therapeutic response to ProSomnus's products Digital Prescription A.I. Device Design • DUCI.. ALGORITHM-DRIVEN MASS CUSTOMIZATION ▪ Highly automated manufacturing process with narrow Al and robotic-driven milling, proprietary algorithm-driven design and finishing Computer Aided Design Computer Assisted Manufacturing Final Quality Control HOW Advanced Materials Robotic Milling BIOMECHANICALLY SUPERIOR DEVICES ▪ ProSomnus devices offer patented biomechanically superior features Enhanced Dual 90⁰ Optipost Anatomical Splint Design Anterior Opening vhf Utility patents cover unique product features, methods and processes, with 8 granted and 15 pending K4 PROSOMNUS SLEEP TECHNOLOGIES Precision Medical Devices COMFORTABLE AND ITERATIVE TECHNOLOGY ▪ Preferred treatment option due to patient comfort and customizability ▪ Titration technology allows for more accurate prescription delivery and higher effectiveness 16 STRICTLY CONFIDENTIAL#17ProSomnus Next Gen Device with Continuous Physiologic Monitoring Poised to Change Sleep Medicine Patent pending, FDA cleared, soft launch expected in Q4 2022 RPM Prototype Device and Patient Mobile App ■ PROSOMNUS SLEEP TECHNOLORIES ▪ Device with embedded sensor enables continuous remote monitoring of medically necessary physiologic metrics - PROSOMNUS® SLEEP TECHNOLOGIES Adherence, oxygen, heart rate, pulse rate, and more ▪ Data transferred from device to cloud via smartphone app ■ Cloud based system allows health care providers to download reports on-demand System enables recurring revenue streams for ProSomnus and healthcare provider Remote patient monitoring codes (99454, 99091, E0486, 99453, 99457) ****** AHI Ⓒ 3.2 AHI ●Normal Total Sleep Apnea Occurrences 39 times Heart Rate 97 BPM High My Report December 1, 2021 Blood Oxygen Ⓒ 94% ●Normal 76% Lowest Heartbeat Rate Variability Beta 46 ms Sleep Movement During Sleep Ⓒ 12 times N Report PROSOMNUS SLEEP TECHNOLOGIES 1:30 PM QE .......... w wwwwwwwwwwww Mine 17 STRICTLY CONFIDENTIAL#18Sales & Marketing to Jointly Drive Growth ProSomnus's efficient commercial infrastructure has significant room for growth and scale in sales coverage while driving patient and provider awareness through marketing initiatives DIRECT SALES INITIATIVE Sales Objective: ■ Educate & Engage ▪ 2 Call Points: Physicians & Dental Providers Build a bi-directional referral relationship ▪ Shift prescriptions from CPAP to ProSomnus 8 2021A $1.8 Forecasted YE Global Direct Sales Rep Count 16-21 30 - 35 $1.6 2022E 2023E 2024E Average Global Sales Rep Productivity ($ millions) 45 - 55 $1.4 $1.4 80-90 2025E $1.5 Conservatively assumes lower average productivity as ProSomnus builds its global sales force PROSOMNUS SLEEP TECHNOLOGIES MARKETING AND BRANDING "PUSH/PULL" INITIATIVE Push ProSomnus to Dentists and Sleep Physicians ■ Targeted clinical education to prove effectiveness ▪ Leverage industry insiders to raise ProSomnus's profile with key clinical audiences ▪ Intended audiences: Power prescribers in North America and worldwide Expand as more physicians practice sleep medicine Pull Patients to Dentists and Sleep Physicians ■ Brand of choice for OSA treatment and increase traffic to providers ▪ Intended audiences: People who have undiagnosed OSA, or hesitate using CPAP People with OSA who have failed CPAP CPAP users interested in a more patient friendly alternative ■ Primary initiatives include: Digital marketing, traditional media advertising and strategic brand positioning 18 STRICTLY CONFIDENTIAL#19Growing Library of Evidence Indicating ProSomnus's Performance World Sleep Congress ¹ March 2022 Precision milled iterative device and material combination appear to yield significantly better results to previously demonstrated data Journal of Dental Sleep Medicine Abstract #0156 March 11-16 2022 MERICAN ACADEMY OF DENTAL SLEEP MEDICINE WORLD SLEEP Rome• Italy 2020 Annual Meeting ~82% of patients, on average, can be treated within 2 millimeters of the initial bite position assuming the standard of care protocol 1. 2. 3. 4. 5. EFFECTS Study² CUREUS SCIENCE V JOURNAL OF EST. 2009 Ap June 2021 Note: Tagline below study reflects key takeaways Effective front-line therapy for Mild/Moderate patients or Severe who refuse CPAP Sleep Science Study7 Sleep Science November 2020 Patients reported reduced daytime sleepiness, reduced snoring and improvements in sleep indicating validity in the oral appliance SLEEP Journal, Vol. 44 Abstract # 434³ S Kent Smith, et al. Efficacy of a Novel Precision Iterative Device and Material. World Sleep Conference. March 2022. Stern J. Efficacy and Effectiveness of the ProSomnus® [IA] Sleep Device for the Treatment of Obstructive Sleep Apnea: EFFECTS Study. Cureus. June 2021. Sall E. Precision Oral Appliance Therapy: The Primetime Treatment for OSA. SLEEP Journal. Vol. 44, Abstract Supplement, 2021. Abstract #434. Page A 172. Elliott E, Ehtessabian J, Murphy M, Rein J, Seltzer N, Schwartz D, Shah S, Smith K. A Multi-Center Preference study of a Novel Oral Appliance Design and Material for Better Provider, Physician, Patient and Payer Acceptance. SLEEP Journal. Vol. 44, Abstract Supplement, 2021. Abstract # 440. Page A 174. Murphy M, Munro K. Device Design's Impact on Dose in Oral Appliance Therapy. Journal of Dental Sleep Medicine. Vol. 8, No. 3 2021. Abstract #004. OXFORD UNIVERSITY PRESS Precision oral appliance is capable of successfully treating patients with all levels of severity 2021 Annual Meeting Sleep Research Society Ⓡ Journal of Dental Sleep Medicine MERICAN DENTAL SLEEP MEDICINE Patients were highly satisfied and devices had little effect on tooth movement and bite changes 6. 7. 2 Year Clinical Study 2019 8. 9. OF 10. Ⓡ SLEEP Journal, Vol. 44 Abstract # 4404 S Sleep Research Society OXFORD UNIVERSITY PRESS 2021 Annual Meeting Patients preferred ProSomnus EVO over CPAP and all other devices similarly designed Journal of Clinical Sleep Medicine⁹ JCSM - Journal of Clinical Sleep Medicine 2017 Annual Meeting In-home feedback-controlled mandibular positioning test able to identify sufferers who will respond to OAT and provides efficacious position Journal of Dental Sleep Medicine Abstract #0045 PROSOMNUS SLEEP TECHNOLOGIES MERICAN ACADEMY OF DENTAL SLEEP MEDICINE Patients of ProSomnus devices are likely to experience fewer side effects that could result in discontinuation of treatment Sall E. Minimization of Titration Protrusion for the Efficient Treatment of OSA. Journal of Dental Sleep Medicine. Vol. 7, No.2 2020. Abstract #015. Kalha A. et al. Comparative assessment of changes in pharyngeal airway space in cases of obstructive sleep apnoea with a customized mandibular repositioning appliance - a clinical study. Sleep Science. 2020; Ahead of Print. Vranjes N. et al. Assessment of Potential Tooth Movement and Bite Changes With a Hard-Acrylic Sleep Appliance: A 2-Year Clinical Study. Journal of Clinical Sleep Medicine. Vol. 6, No. 2 2019. Remmers J. et al. A Feedback-Controlled Mandibular Positioner Identifies Individuals With SleepApnea Who Will Respond to Oral Appliance Therapy. Journal of Clinical Sleep Medicine. Vol. 13, No. 7 2017. 2021 Virtual Annual Meeting Journal of Dental Sleep Medicine ¹0 Charkhandeh S. et al. A Fully Digital Workflow and Device Manufacturing for Mandibular Repositioning Devices for the Treatment of Obstructive Sleep Apnea: A Feasibility Study. Journal of Dental Sleep Medicine. Vol 4, No. 4 2017. MERICAN CADEMY OF DENTAL SLEEP MEDICINE R It is feasible with predictable outcomes, and patients prefer devices from a fully digital workflow Feasibility Study 2017 19 STRICTLY CONFIDENTIAL#20Front Line OSA Therapy (FLOSAT Study) Medical Affairs: Active Studies ProSomnus continues to invest in clinical support and professional education, far exceeding previous clinical data for legacy OAT Study Severe OSA Indication (SOS Study) Harvard Brigham's Hypoxic Burden Study Objective Compare the efficacy of ProSomnus with CPAP as frontline therapy Secure FDA severe OSA indication for use by demonstrating safety and effectiveness Does ProSomnus reduce hypoxic burden for patients with OSA, which is predictive of cardiovascular events? Design Prospective, controlled, cross over trial Prospective, controlled, single arm, multi-center, trial Prospective, controlled, single arm trial Other Studies: Dose study, Mt. Sinai Hospital ▪ 5 scientific abstracts accepted for publication at World Sleep Congress ▪ 5 scientific abstracts accepted for publication at AADSM Meeting ■ 4 scientific abstracts accepted for publication at AASM Meeting Status 40/121 patients enrolled FDA-approved study design Q1 '22 O 28/28 enrolled; 8/28 at 1-year follow up PROSOMNUS SLEEP TECHNOLOGIES Expected Next Steps Preliminary data available in Q4 '22 Enroll patients by end of Q2 '22 Preliminary results show clinically significant improvements in hypoxic burden 20 STRICTLY CONFIDENTIAL#21Exceptional Management Team with Deep Medical and Dental Device Expertise ProSomnus's management team has experience disrupting industries with breakthrough innovations I ■ Founding member of ProSomnus ■ Prior to MicroDental, spent 10 years at 3M Company and Stryker Corporation, with a focus in Dental and Orthodontics Previously was the President of MicroDental Laboratories 3M ■ ■ MICRODENTAL Len Liptak, MBA Chief Executive Officer LABORATORIES Nobel Biocare Has 40 years of sales experience and executive leadership in the medical and dental industry Previously was responsible for sales and management in both North and Latin America for Nobel Biocare PANTHERA stryker Jerry Vogel VP of Sales, North America MASIMO ■ Chairwoman and founding member of ProSomnus Managing Director at HealthpointCapital since 2004 Formerly served as a director at BioHorizons and MicroDental Laboratories MICRODENTAL HEALTHPOINTCAPITAL Laing Rikkers Chairwoman LABORATORIES Previously area and regional sales manager for ProSomnus Prior experience as strategic account manager at Panthera Dental PANTHERA Greg Vogel Associate VP, International Business 0 ■ ■ ■ Founding member of ProSomnus Previously was the Engineering Director of MicroDental Laboratories Prior to MicroDental, worked for 3M Company for over 7 years with a focus in Dental and Orthodontics 3M MICRODENTAL Sung Kim Chief Technology Officer Diplomate of the American Board of Dental Sleep Medicine ■ Serves on the Adjunct Faculty at the University of Detroit Mercy and oversees the Practice and Financial Management Curriculum at the Pankey Institute DETROIT MERCY DENTAL Mark Murphy, DDS, FAGD Lead Clinical Facility PANK FITUR ■ Joined ProSomnus in June 2017 Prior to joining ProSomnus, was the VP of Finance at AMP Printing and The National Food Laboratory Previously was the VP of Finance and Accounting at MicroDental MICRODENTAL LABORATORIES ERNST & YOUNG Mindy Hungerman, CPA Chief Financial Officer № Recognized physiologist, physician, pioneer & innovator in sleep medicine UNIVERSITY OF CALGARY NATIONAL FOOD Clinical professor at the University of Calgary with an active sleep practice at the Foothills Medical Centre John Remmers, MD Medical Director ZEPHYR Sleep Tochnologies ■ I PROSOMNUS SLEEP TECHNOLOGIES Prior to joining ProSomnus, was Director of Clinical Education for MicroDental Laboratories Prior to MicroDental, worked for San Francisco Bay Area Graphic Design firms in Project Management MICRODENTAL Heather Whalen VP of Marketing Communications LABORATORIES Board certified in Otolaryngology and Sleep Medicine Operates one of the premier and busiest Sleep Medicine practices in North America StopSnoring SleepBetter Ed Sall, MD, DDS, MBA Medical Director 21 STRICTLY CONFIDENTIAL#22Significant Growth Potential and Attractive Financial Prospects CAGR NET REVENUE (2020A - 2023E) ($ in millions) $8 2020A Growth Rate 50% GROSS MARGIN (2020A - 2023E) ($ in millions) 2020A $14 ~400 basis point impact due to supply chain disruptions Adj. EBITDA Margin 2021A Unlevered Free Cash Flow¹ 70% 52% 2021A (25%) ($3) ~70% $20-21 2022E ~45% Q1 '22 Gross Margin ~58% ~59% 2022E ~(15%) ~($6) $38-40 2023E ~90% ~65% 2023E ~(5%) ~($6) KEY REVENUE DRIVERS PROSOMNUS SLEEP TECHNOLOGIES ▪ North America direct sales rep expansion from 8 in 2021 to >20 in 2023 ▪ Expansion into international markets, and hiring of direct sales reps in Europe ▪ DTC advertising to drive patient awareness and clinician education to ProSomnus Oral appliance benefits ■ Additional revenue stream associated with Remote Patient Monitoring capabilities in pipeline product (expected soft launch in Q4 '22) KEY GROSS MARGIN DRIVERS ■ Product mix shifting to higher margin EVO and RPM related revenue ▪ Software upgrades, automation and process improvement initiatives are aimed at lowering direct material and direct labor costs ■ Transition of manufacturing to a lower cost jurisdiction expected to provide significant margin improvement related to direct labor ■ Purchasing scale and volume discounts anticipated to lower direct material costs ■ Economies of scale expected to drive lower overhead as a % of revenue Note: ProSomnus previously disclosed to certain parties certain financial prospects for calendar years ending 2024 and 2025. These financial prospects included 2024 and 2025 revenue of $70-74M and $120-125M, respectively; 2024 and 2025 gross margin of ~68% and ~70%, respectively; 2024 and 2025 Adj. EBITDA margin of ~3% and ~14%, respectively; and 2024 and 2025 unlevered free cash flow of ($5M) and $5M, respectively. ProSomnus is no longer issuing guidance for its financial prospects in 2024 and 2025. 1. Unlevered Free Cash Flow defined as Cash Flow from Operations (unlevered) less Cash Flow from Investing less Equipment Lease Financing. Does not include transaction costs. 22 STRICTLY CONFIDENTIAL#23Transaction Summary(¹)(2) OVERVIEW ▪ ProSomnus is being acquired by Lakeshore Acquisition I (“LAAA"), a publicly listed special purpose acquisition company with $55M cash in trust ■ Consideration for ProSomnus includes 11.2M shares of LAAA common stock - ProSomnus shareholders are eligible to receive 3M additional common shares (the "earn-out shares") of the combined company across 3 different tranches if the stock trades at or above $12.50, $15.00 and $17.50 ▪ LAAA has signed a term sheet whereby $15M of Senior Secured Convertible Notes and $15M of non-binding Junior Secured Convertible Notes are expected to fund into LAAA at close of merger(³) ▪ Pro forma market cap of $199M and enterprise value of $168M ▪ Pro forma net cash of $64M after estimated fees and expenses 6% 1. 2% 5% 32% 56% PRO FORMA OWNERSHIP Existing ProSomnus Shareholders Existing Lakeshore Shareholders (4) Lakeshore Sponsor Fees & Expenses (in stock) Lenders (5) Total Uses Excludes 4.1M public warrants and 0.2M sponsor warrants at an $11.50 strike price as well as the impact of any potential earn-out shares 2. Assumes no redemptions from LAAA trust 3. Funding is subject to signing the definitive convertible debt agreements 4. Includes up to 810k Additional Shares, comprised of up to 410k Sponsor promote shares, to be matched by up to 410k of newly issued Company shares to incentivize non-redeemers or equity PIPE investors 5. 6. 56% 32% 6% 5% 2% 100% PRO FORMA VALUATION SUMMARY in millions (except per share data) Shares Outstanding Assumed Price Per Share Market Capitalization Plus: Debt Less: Cash Enterprise Value EV / 2022E Revenue (6) EV / 2023E Revenue (6) SOURCES Cash Remaining in Lakeshore Trust ProSomnus Equity Roll Convertible Debt Proceeds Total Sources USES PROSOMNUS SLEEP TECHNOLOGIES ProSomnus Equity Roll Debt Paydown Fees & Expenses (Estimated) Cash to Balance Sheet Total Uses Select lenders will receive up to 300k additional shares, subject to signing the definitive convertible debt agreements; does not reflect potential future issuances of shares upon conversion of convertible debt, which could be substantially dilutive Assumes midpoint of revenue range 19.9 $10.00 $199 $34 $65 $168 8.2x 4.3x $55 $112 $30 $196 $112 $13 $7 $64 $196 23 STRICTLY CONFIDENTIAL#24Select Public Comparables ProSomnus is appropriately priced relative to comps and on a growth adjusted basis OSA Leaders Disruptive Consumer Devices (Median) Disruptive Med Tech (Median) Inspire Sleep Apnea Innovation ResMed hydrafacial align > Butterfly™ INARI Network MEDICAL pulmonX\] SILKROAD> O Ⓡ .Outset SHOCKWAVE MEDICAL INC PROSOMNUSⓇ SLEEP TECHNOLOGIES EV / '23E Revenue Multiple '21E - '23E Revenue CAGR 10.2 x 7.2 X 4.2 X 6.5 x 4.3 x Source: Company filings, Wall Street Research and Capital IQ estimates as of May 6, 2022 1. 2023E Growth Adjusted Revenue Multiple calculated as EV / 2023E Revenue divided by 2021E - 2023E Revenue CAGR 39% 10% 20% 34% 67% PROSOMNUS SLEEP TECHNOLOGIES Growth Adj. '23E Revenue Multiple¹ 0.26 x 0.74 x 0.23 x 0.17 X 0.06 x 24 STRICTLY CONFIDENTIAL#25An Opportunity to Transform the OSA Market O 1 PROSOMNUS® SLEEP TECHNOLOGIES 7 OSA is a Massive, Rapidly Growing and Underserved Market 2 3 6 ProSomnus Precision OAT Devices Deliver a Patient-Preferred, Clinically Proven and More Economical Treatment 4 5 Patented, Innovative Technologies & Digital Capabilities Create More Effective & Preferred Outcomes Efficient Commercial Model Focused on Sleep Dentists as Therapy Providers PROSOMNUS SLEEP TECHNOLOGIES Multiple Expected Upcoming Catalysts to Drive Market Conversion Including Remote Patient Monitoring Attractive Growth Trajectory and Financial Profile Experienced Team to Lead ProSomnus Through Next Stage of Growth 25 STRICTLY CONFIDENTIAL#26O PROSOMNUS SLEEP TECHNOLOGIES Appendix "The precision engineering used in fabricating ProSomnus Medical Devices is second to none. They make me a better sleep dentist." B. Kent Smith, DDS, D.ABDSM, D.ASBA#27Current Treatment Options Deliver Low Levels of Disease Alleviation and are Costly Mechanism of Action OSA Indications Incumbent Therapy Limitations I I I CPAP X Forces Air Down Throat X Low adherence rates (<50% at months) X Expensive X Discomfort X Mild, Moderate & Severe X Mask leakage Social stigma Limited portability Note: Diagnosing physician for each treatment modality is a Sleep Physician X X X X Legacy OAT Positions Jaw Forward Arbitrary Jaw Thrust Mild & Moderate Bulky, uncomfortable Unhygienic / color change Lack of durability / reliability / predictability Largely manual titration (limits efficacy and increases cost) X Surgical Implant Stimulates Tongue X X X PROSOMNUS SLEEP TECHNOLOGIES X Upper Airway Stimulation Moderate & Severe (Failed CPAP) Relatively unproven Invasive / surgery Required Expensive Reimbursement complexities Only applicable to a subset of moderate / severe patients who are unable to use CPAP 27 STRICTLY CONFIDENTIAL#28ProSomnus Products Outperform the Competition We believe that ProSomnus is the only OSA treatment solution that has scientifically demonstrated both American Academy of Sleep Medicine ("AASM") and American Academy of Dental Sleep Medicine's ("AADSM") definitions of an effective OAT¹ EFFECTIVENESS ■ Effectiveness is a key driver of treatment selection for physicians and patients ■ The effectiveness advantage of ProSomnus devices is a function of: - Significantly better adherence rates Strong efficacy rates Superior Effectiveness2,3,4,5 ProSomnus (Mild/Moderate) ProSomnus (All Severities) CPAP Upper Airway Stimulation 1. Legacy OAT 50% 48% 45% 85% 74% PATIENT PREFERENCE Patients are satisfied when their symptoms are alleviated ■ Patients have been shown to strongly favor ProSomnus devices over alternatives ■ ProSomnus patient satisfaction advantage is driven by comfort, effectiveness and human factors Superior Patient Satisfaction Prefer ProSomnus over my CPAP Wear my ProSomnus more than I wear my CPAP Find my ProSomnus device easier to clean than CPAP Prefer ProSomnus over my previous (legacy) OAT Mogell, K. et al. Definition of an Effective Oral Appliance for the Treatment of Obstructive Sleep Apnea and Snoring. JDSM 6.3. 2019. Ramar, K et al. Clinical Practice Guideline for the Treatment of OSA. JCSM 11.7.2015 2. ProSomnus adherence: Stern, J. Efficacy and Effectiveness 2018 Jun; ProSomnus efficacy: Mosca et al. JCSM 2022; 18(3):911-919. 3. CPAP adherence and efficacy: Dieltjens M, et al. Oral Appliances in Obstructive Sleep Apnea 2019 Nov 8 4. Upper Airway Stimulation Adherence: Thaler et al. Results of the ADHERE UAS Registry. Laryngoscope (130) 2020. UAS Efficacy: Strollo, STAR Trial Group. Upper-airway stimulation for obstructive sleep apnea. N Engl J Med. 2014 Jan 9 5. Legacy OAT adherence: Dieltjens M, et al. Objectively Measured vs. Self-Reported Compliance 2013 Nov; Legacy OAT 100% 100% 100% 100% 6. 7. 8. 9. HEALTHCARE ECONOMICS ■ The cost of therapy is an important consideration for payors and healthcare providers ProSomnus's cost advantages are driven by low initial cost and few remake issues ■ ▪ Digital process enables ProSomnus to produce a new device more cost effectively than competitors Lower Cost Per Day than Alternative Therapy Devices7,8,9 ProSomnus OAT CPAP Legacy OAT Neurostimulation $1.30 $2.99 $3.23 $41.10 efficacy: Dieltjens M et al. Oral Appliances in OSA 2019 Nov ProSomnus EVO IRB survey. AASM Scientific Abstract Presentation 2021. 2021 AADSM abstract SIDE EFFECTS Side effects are defined as events that result in the discontinuation of therapy, which lead to a reduction in adherence and ultimately effectiveness ▪ ProSomnus devices have been engineered, based on specific design inputs, to mitigate side effects (short- and long-term) Less Discontinuation of Treatment Due to Side Effects 10,11,12 ProSomnus OAT PROSOMNUS SLEEP TECHNOLOGIES Neurostimulation Legacy OAT CPAP Legacy OAT and neurostimulation cost per day based on internal management analyses Measures cost of therapy as the quotient of the reimbursement cost and the warranty period for the device ProSomnus Quality Management System Data, 2020 10. 11 Bestourous, Adverse events associated with the Inspire. Am J Otolaryngol. 2020 Jun 25 12. Ramar K, et al. Clinical practice guideline for the treatment of OSA. Journal of Dental Sleep Medicine 2015 0% 3% 5% 8% 28 STRICTLY CONFIDENTIAL#29Low Adherence Limits Effectiveness of CPAP Therapy CPAP is the current leading therapy for OSA, but inherent design flaws and patient-experience drawbacks mean adherence (hours worn) has barely changed in 20 years CPAP MANUFACTURERS X X X REASONS FOR CPAP NON-ADHERENCE X X ResMed X PHILIPS RESPIRONICS Fisher&Paykel HEALTHCARE Mask discomfort Mask leakage Claustrophobia Pressure intolerance Skin irritation Noise from bedside pump X Nasal congestion X X X X Nosebleeds Nasal drying Inconvenience of device / consumables maintenance Lack of intimacy, partner disturbance, social issues X Limited portability CPAP ADHERENCE - HOURS WORN¹,2,3 3.9 Hours Despite significant investment and innovation, CPAP adherence has barely changed in 20 years ProSomnus devices demonstrated 60.7%ª better mean nightly use in clinical studies CPAP: 1999 1. Rotenberg BW, Murariu D, Pang KP. Trends in CPAP adherence over twenty years of data collection: a flattened curve. J Otolaryngol Head Neck Surg. 2016 Aug 19 2. Dieltjens M, Vanderveken O. Oral Appliances in Obstructive Sleep Apnea. Healthcare (Basel). 2019 Nov 8 3. Stern, J. Efficacy and Effectiveness. Annual Meeting of the AADSM, 2018 Jun 4. Calculated as % increase from 4.5 hours to 7.2 hours 60.7% O 4.5 Hours PROSOMNUS SLEEP TECHNOLOGIES CPAP: 2019 7.2 Hours ProSomnus 29 STRICTLY CONFIDENTIAL#30ProSomnus is NOT Like Other OATS ProSomnus device technology addresses the limitations of legacy OATS and results in superior performance DATA SUPPORTS PROSOMNUS HAS A SUPERIOR PRODUCT¹ NORTH AMERICAN REVENUE GROWTH VS. OAT COMPETITOR % AHI Improvement ProSomnus has +1,800bps Better Mean AHI Improvement 70% 65% 60% 55% 50% 45% 1. 0 Competitor #1 Style Legacy Medicare Devices 100 200 Competitor #3 Style Competitor #2 Style 300 400 Total Sample Size Comfortable and easy-to-use Clinically superior due to precision, titration and customizability 500 ProSomnus 600 700 ProSomnus EVO is the #1 U.S. Prescribed OAT PROSOMNUS SLEEP TECHNOLOGIES Competitor #2 2 3 2020A 2021A Growth ProSomnus Addresses Key Issues With Legacy OATS Minimal side effects, staining or bio-gunk More economical and durable, with single low cost payment every 3 to 5 years PROSOMNUS SLEEP TECHNOLOGIES 19% 67% 2017A-2021A CAGR ~40% 1% Significantly faster patient journey time and product manufacturing turnaround Digital Al-driven manufacturing Ramar K, Dort LC, Katz SG, Lettieri CJ, Harrod CG, Thomas SM, Chervin RD. Clinical practice guideline for the treatment of obstructive sleep apnea and snoring with oral appliance therapy: an update for 2015. Journal of Dental Sleep Medicine 2015;2(3):71- 125. ProSomnus meta-analysis based upon 7 studies published in peer reviewed medical journals, last updated July 2021. Represents ProSomnus North America prescriber sales growth 2. 3. Represents Competitor #2 North America segment revenue growth; graph represents revenue growth on a calendar year basis 30 STRICTLY CONFIDENTIAL#31I Why are Patients More Adherent With ProSomnus Devices? T I T Smaller & More Comfortable ProSomnus devices allow for significantly more room for the tongue, rather than pushing the tongue back like Legacy OAT¹ Comparison of Tongue Space in Mouth with Device² !Tongue Space Remaining I After ProSomnus Device I Insertion (10.3mm) I I 1. 2. 3. 4. PROSOMNUS SLEEP TECHNOLOGIES O Maximum Spacing within Mouth (~12mm) ~30% smaller overall profile than Legacy OAT ~4.5x larger area for tongue space ~3mm lateral freedom of movement Legacy OAT Tongue Space Remaining After Legacy OAT Device Insertion (1.7mm) Maximum Spacing within Mouth (~12mm) X X 1 I Bulky material Limited lateral freedom of movement I || I I I I I 1 1 X Airway space clogged by design I and manufacturing limitation II I I I I I I I I 1 I Less porosity equals less bio-gunk for ProSomnus³ More Hygienic Color-Difference Test Results: 10-Day Mustard Staining 3.2 PROSOMNUS SLEEP TECHNOLOGIES 7.5 CPAP Mask 27.3 Legacy OAT No clinically or statistically significant tooth movement or bite changes for ProSomnus4 Comparison of Dental Side Effects from OAT4 (in millimeters) 0.0 Fewer Side Effects 0.8 Change in Lower Incisors 0.0 PROSOMNUS SLEEP TECHNOLOGIES 0.5 Change in Upper Incisors PROSOMNUS SLEEP TECHNOLOGIES Murphy, M. Abstract presented at 2021 AADSM meeting Hu, J. et al. Abstract presented at 2021 AADSM meeting and Company data; mm denotes millimeters Gelb, M. Say No to Bio-Gunk. Dental Sleep Insider. 2018 Vranjes N, Santucci G, Schulze K, Kuhns D, Khai A. Assessment of potential tooth movement and bite changes with a hard- acrylic sleep appliance: A 2-year clinical study. J Dent Sleep Med. 2019 0.0 1.6 Change in Overjet 0.0 0.7 Change in Overbite Legacy OAT 31 I I I STRICTLY CONFIDENTIAL#32I L 4₁ 4₁ 4 4 I Why is ProSomnus More Efficacious Than Legacy OAT? I I I ! Legacy OAT I I I Ir II Proprietary manufacturing technology enables ~7x more accurate prescription transfer || II 11 | I Precision Prescription Transfer Prescription Transfer Error (in millimeters)¹ I i Legacy OAT I I PROSOMNUS SLEEP TECHNOLOGIES PROSOMNUS SLEEP TECHNOLOGIES 1. 2. 3. 4. 5. 0.3 Efficacy Loss %4 3% 3.7 37% I T 1 I I I Patented titration mechanism mitigates risk of efficacy loss during sleep Jaw Movement During Sleep (mm) Efficacy Loss % with Jaw Movement due to Mechanism Design² 15 Titration Mechanism Innovation 10 5 0% 0% 0% 0% 4% 18% Hu, J. et al. Abstract presented at 2021 AADSM meeting Implication of Kato, 2000, applied to prescription transfer error and difference in lingual space Kato J, et al. 2000 PROSOMNUS SLEEP TECHNOLOGIES 36% Legacy OAT 55% I I I IL 4 I 4 1 4 T I Precision Anatomical Device Design Patented, anatomically precise, device design promotes better treatment mechanisms Tongue Space Impact by Device (in millimeters)³ Legacy Oat PROSOMNUS SLEEP TECHNOLOGIES Legacy OAT PROSOMNUS SLEEP TECHNOLOGIES PROSOMNUS SLEEP TECHNOLOGIES 1.5 Efficacy Loss %4 15% Why does this matter? ProSomnus precision OAT devices improve treatment outcomes by reducing the risk of efficacy loss; Studies suggest each 2 millimeters of error is associated with a 20% change in treatment efficacy5 Hu, J. et al. Abstract presented at 2020 AADSM meeting Kato J, Isono S, Tanaka A, Wantabe T, Araki D, Tanzawa H, Dose-dependent effects of mandibular advancement on pharyngeal mechanics and nocturnal oxygenation in patients with sleep-disordered breathing. 2000 April 17, follow-on analysis 6.7 67% 32 I I I | I STRICTLY CONFIDENTIAL#33ProSomnus Was Purposefully Designed To Be Different From Other OATS > Mechanism of Action Medical Grade Material OSA Biomechanical Design Precision Manufactured Scaled Clinical Data (n > 500) AASM/AADSM¹ Recognized High Growth (+50% Rev. Growth)² Scaled Adoption (20k+ Patients Treated Per Year) Source: ProSomnus Management Estimates 1. 2. Competitor #1 Arbitrary Jaw Thrust X X X X X X Competitor #2 Arbitrary Jaw Thrust American Academy of Sleep Medicine and American Academy of Dental Sleep Medicine High growth defined as >50% 2020-2021 North America Product Revenue Growth X X X X Competitor #3 Arbitrary Jaw Thrust X X X X X Competitor #4 Jaw Expansion X X X X X X X PROSOMNUS SLEEP TECHNOLOGIES PROSOMNUS SLEEP TECHNOLOGIES Precision Jaw Repositioning 33 STRICTLY CONFIDENTIAL#34The ProSomnus Product Portfolio Delivers OSA Solutions for a Variety of Patients ProSomnus's devices are preferred by patients, clinically effective and offer attractive economics to all stakeholders ProSomnus EVO Most Prescribed OAT Device in the United States Next generation device made from a high performance, medical grade material ProSomnus Iterative Advancement [IA] The first device designed for precision OAT Medicare ProSomnus Precision Herbst [PH] ProSomnus advantages for Medicare patients PROSOMNUS SLEEP TECHNOLOGIES ProSomnus Continuous Advancement [CA] Precision and comfort for complex jaw alignment In Development ProSomnus Remote Patient Monitoring Remote therapeutic and physiologic patient monitoring 34 STRICTLY CONFIDENTIAL#35Prosomnus Purposely Designed an Oral Appliance that Addresses the Limitations of Alternative Therapies ProSomnus's devices feature patented technologies that enable preferred treatment outcomes Patented Technologies Titration Mechanism: Iterative Unique titration technology that enhances comfort and ease of use Titration Mechanism: 90 Degree Maintains prescription if patient opens mouth during sleep Precision Prescription Transfer Reposition jaw within 0.3 millimeters of prescription O Engineered Materials Proprietary, engineered materials, optimized for performance Personalization Individualize each device to match unique needs for each patient O Biomechanics: 1. 2020 AADSM Conference abstract PROSOMNUS SLEEP TECHNOLOGIES OBiomechanics: True Anatomy ProSomnus precision devices mirror the patient's dental anatomy, for comfort Biomechanics: Volume 2.6x less volume in the mouth, for better adherence Biomechanics: Lip Seal 54% more room for the lip seal, a critical aspect for successful therapy Biomechanics: Tongue Space 78% more tongue space, a critical aspect for successful therapy All comparison in relation to legacy OAT devices¹ 35 STRICTLY CONFIDENTIAL#36More Patient-Friendly Alternatives and DTC Marketing Have Transformed Established Markets Before Consumers are pre-positioned to act on ProSomnus's DTC marketing in Dental / OSA market following decades of investment from peers *invisalign Align created a more user-friendly, effective alternative (Invisalign) to legacy orthodontic braces and experienced exponential growth and created significant value Invisalign has treated over 10 million patients, mainly through consumer marketing efforts and educating and training dentists ALIGN REVENUE & MARKET CAPITALIZATION (2001A - 2021A)¹ ($ in millions) Market Capitalization $45 2001A $51,821 $3,942 2021E ■ ▪ Inspire is trying to convert the moderate to severe failed CPAP market; while Inspire has experienced early success, it requires an expensive surgical procedure and to date has only treated ~20k patients Emphasis on DTC and physician marketing initiatives, including Facebook, Google, radio and TV advertisements, to create awareness and educate patients and providers Market Capitalization PROSOMNUS SLEEP TECHNOLOGIES Inspire Sleep Apnea Innovation INSPIRE REVENUE & MARKET CAPITALIZATION (2017A - 2021A)² ($ in millions) $29 2017A Source: Capital IQ and public filings; Market capitalizations as of December 31, 2021. 1. Invisalign Q1 2021 investor presentation Market capitalization calculated based on $16 IPO pricing and ~20 million initial shares outstanding from Inspire S-1A (May 2, 2018); Inspire closed its IPO on May 3, 2018 2. $6,294 $233 2021E 36 STRICTLY CONFIDENTIAL#37Incumbent Therapies Do Not Meet Continuous Physiologic (Oxygen) Monitoring Needs of Sleep Medicine ProSomnus will be the first therapy to achieve continuous physiologic monitoring CONTINUOUS THERAPEUTIC MONITORING Entails sensors that monitor the function and performance of therapy, but not the patient's physiologic response X X Limited value Not predictive of health outcomes for OSA X Unclear reimbursement Therapy Type ADHERENCE CPAP Upper Airway Stimulation Legacy OAT ProSomnus (Current) No Monitoring Capabilities SomnoMed Narval POSITION ■ ProSomnus H Vivos X TECHNOLOGY EVOLUTION OF OSA DEVICES X AIRFLOW X X X ■ ProSomnus (2018) ■ ResMed ■ Philips Respironics CONTINUOUS PHYSIOLOGIC MONITORING ■ Entails sensors that monitor a patient's physiologic response to a therapy Predictive of OSA Reimbursement available Therapy Type CPAP Upper Airway Stimulation Legacy OAT Therapeutic Monitoring Inspire ■ SomnoMed (2023E) ProSomnus (Q4 2022) OXYGEN X X X HEART RATE ■ X X PROSOMNUS SLEEP TECHNOLOGIES X PULSE RATE X X X Continuous Physiologic Monitoring ProSomnus (Q4 2022E) 37 STRICTLY CONFIDENTIAL I I#38Non-GAAP Adjusted EBITDA Reconciliation $ in millions Net Income (Loss) (+) Foregiveness of PPP Loans (+) Other Expenses (Income) (+) Interest Expense (+) Provision for Income Tax Expense (+) Depreciation and Amortization (+) DeSPAC Costs & Select Severance Adjusted EBITDA Adjusted EBITDA Margin $ $ FY2021A (6) (2) 0 3 1 0 (4) (25%) PROSOMNUS SLEEP TECHNOLOGIES 38 STRICTLY CONFIDENTIAL